

SYMDEKO (tezacaftor/vacaftor, oral)

Diagnosis Considered for Coverage:

- Cystic fibrosis with the presence of cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation sensitive to Symdeko

Coverage Criteria:

For diagnosis listed above:

- Patient is at least 6 years old, **and**
- Not being used in combination with another CFTR modulator agent (e.g. Kalydeco, Orkambi, Trikafta), **and**
- Dose does not exceed FDA label maximum, **and**
- Documented presence of BOTH (homozygous) F508del mutations OR at least one non-F508del mutation of the CFTR gene responsive to Symdeko.

Coverage Duration: one year

Effective Date: 5/31/2023